Key Takeaways
- Sector: Healthcare, Healthtech & Medtech, Business Services.
- Geography: United States.
Analysis
Decera Clinical, a portfolio company backed by global investment firm The Riverside Company, has significantly expanded its service offerings by acquiring Onviv, Inc. This strategic move enhances Decera Clinical's capacity as a premier scientific activation partner for the life sciences sector, integrating Onviv's specialized expertise in real-world intelligence, scientific communications, and stakeholder engagement.
The integration of Onviv, established in 2015, brings a suite of capabilities that complement Decera Clinical's existing strengths. This union is designed to empower healthcare professionals and life sciences organizations to navigate an increasingly complex environment, accelerate innovation pipelines, and translate scientific evidence into actionable strategies. The combined entity aims to drive improved patient outcomes and foster greater collaboration across the healthcare ecosystem.
Peter Tsang, Co-Chief Investment Officer at Riverside Capital Appreciation Fund (RCAF), highlighted the strategic alignment of the acquisition. "This investment underscores our dedication to backing mission-driven businesses at the nexus of healthcare, technology, data, and human expertise," Tsang stated. "Both Decera Clinical and Onviv possess distinct market advantages, and their combined forces are exceptionally positioned for sustained growth and value creation." The Riverside Company has a long-standing focus on the healthcare sector, having invested in over 220 platform and add-on companies since 1988.
Leo Tarkovsky, CEO of Decera Clinical, expressed enthusiasm for the integration. "We are thrilled to welcome Onviv's accomplished team," Tarkovsky remarked. "Their complementary skills will amplify our ability to serve clients and expand our collective impact." He further noted that Onviv's go-to-market strategies will be accelerated through Decera Clinical's proprietary AI platform, ActivationOS, which consolidates data, workflows, and intelligence into a unified system, promising enhanced commercial and clinical execution.
Jeff Meehan, Founder and CEO of Onviv, echoed the sentiment of strategic synergy. "From our initial discussions, it was evident that our organizations shared a profound commitment to innovation, scientific rigor, and advancing healthcare outcomes," Meehan commented. "Joining Decera Clinical will enable us to deliver even greater value and impact to our partners and the broader healthcare community." This acquisition represents a significant step in Decera Clinical's growth trajectory following The Riverside Company's initial investment in 2020.
The transaction saw significant involvement from The Riverside Company's deal team, including Principal Mark Fishman, Vice President Peter Muncey, Associate Barron Fletcher, and Capital Markets Senior Partner Anne Hayes. Origination Partner Grant Marcks was instrumental in sourcing the deal. Excel Partners served as the exclusive financial advisor to Onviv, Inc. The life sciences consulting and communications market is a dynamic segment within the broader healthcare services industry, driven by increasing R&D complexity and the need for effective scientific dissemination.